APO Research
Talk to an analyst

APO RESEARCH · REPORT

PD-1/PD-L1 Checkpoint Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global PD-1/PD-L1 Checkpoint Inhibitors Market Outlook and Growth Opportunities 2026

29 December 2025193 pages

Choose your research edition.

Industry ResearchPD-1/PD-L1 Checkpoint Inhibitors Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-1/PD-L1 Checkpoint Inhibitors Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal PD-1/PD-L1 Checkpoint Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-1/PD-L1 Checkpoint Inhibitors Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-1/PD-L1 Checkpoint Inhibitors Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global PD-1/PD-L1 Checkpoint Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for PD-1/PD-L1 Checkpoint Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PD-1/PD-L1 Checkpoint Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PD-1/PD-L1 Checkpoint Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the PD-1/PD-L1 Checkpoint Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the PD-1/PD-L1 Checkpoint Inhibitors market include Merck, Junshi Biosciences, Pfizer, Hengrui Pharmaceuticals, Roche, Regeneron Pharmaceuticals, Bristol Myers Squibb and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global PD-1/PD-L1 Checkpoint Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PD-1/PD-L1 Checkpoint Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PD-1/PD-L1 Checkpoint Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PD-1/PD-L1 Checkpoint Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

PD-1/PD-L1 Checkpoint Inhibitors Segment by Company

Merck

Junshi Biosciences

Pfizer

Hengrui Pharmaceuticals

Roche

Regeneron Pharmaceuticals

Bristol Myers Squibb

AstraZeneca

PD-1/PD-L1 Checkpoint Inhibitors Segment by Type

PD-1 Inhibitors

PD-L1 Inhibitors

PD-1/PD-L1 Checkpoint Inhibitors Segment by Application

Gastric Cancer

Squamous Cell Skin Cancer

Melanoma

Non-small Cell Lung Cancer

Other

PD-1/PD-L1 Checkpoint Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global PD-1/PD-L1 Checkpoint Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions PD-1/PD-L1 Checkpoint Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify PD-1/PD-L1 Checkpoint Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze PD-1/PD-L1 Checkpoint Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1/PD-L1 Checkpoint Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-1/PD-L1 Checkpoint Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1/PD-L1 Checkpoint Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PD-1/PD-L1 Checkpoint Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PD-1/PD-L1 Checkpoint Inhibitors industry.

Chapter 3: Detailed analysis of PD-1/PD-L1 Checkpoint Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of PD-1/PD-L1 Checkpoint Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of PD-1/PD-L1 Checkpoint Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. PD-1/PD-L1 Checkpoint Inhibitors Industry Trends Table 2. PD-1/PD-L1 Checkpoint Inhibitors Industry Drivers Table 3. PD-1/PD-L1 Checkpoint Inhibitors Industry Opportunities and Challenges Table 4. PD-1/PD-L1 Checkpoint Inhibitors Industry Restraints Table 5. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Share by Company (2021-2026) Table 7. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume by Company (K Units) & (2021-2026) Table 8. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume Share by Company (2021-2026) Table 9. Global PD-1/PD-L1 Checkpoint Inhibitors Average Price (US$/Unit) of Company (2021-2026) Table 10. Global PD-1/PD-L1 Checkpoint Inhibitors Company Ranking, (2024-2026) & (USD Million) Table 11. Global PD-1/PD-L1 Checkpoint Inhibitors Key Company Manufacturing Base & Headquarters Table 12. Global PD-1/PD-L1 Checkpoint Inhibitors Company, Product Type & Application Table 13. Global PD-1/PD-L1 Checkpoint Inhibitors Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global PD-1/PD-L1 Checkpoint Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of PD-1 Inhibitors Table 18. Significant Companies of PD-L1 Inhibitors Table 19. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume by Type (2021-2026) & (K Units) Table 21. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume by Type (2027-2032) & (K Units) Table 22. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume Share by Type (2021-2026) Table 23. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume Share by Type (2027-2032) Table 24. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type (2021-2026) Table 28. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Gastric Cancer Table 30. Significant Companies of Squamous Cell Skin Cancer Table 31. Significant Companies of Melanoma Table 32. Significant Companies of Non-small Cell Lung Cancer Table 33. Significant Companies of Other Table 34. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume by Application (2021-2026) & (K Units) Table 36. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume by Application (2027-2032) & (K Units) Table 37. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume Share by Application (2021-2026) Table 38. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume Share by Application (2027-2032) Table 39. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application (2021-2026) Table 43. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application (2027-2032) Table 44. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region (2021-2026) & (K Units) Table 46. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Region (2021-2026) Table 47. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region (2027-2032) & (K Units) Table 48. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Region (2027-2032) Table 49. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Region (2021-2026) Table 52. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Region (2027-2032) Table 54. Global PD-1/PD-L1 Checkpoint Inhibitors Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global PD-1/PD-L1 Checkpoint Inhibitors Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2026) & (K Units) Table 59. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country (2021-2026) Table 60. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2027-2032) & (K Units) Table 61. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country (2027-2032) Table 62. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value Market Share by Country (2021-2026) Table 64. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value Market Share by Country (2027-2032) Table 66. Merck Company Information Table 67. Merck Business Overview Table 68. Merck PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Merck PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 70. Merck Recent Development Table 71. Junshi Biosciences Company Information Table 72. Junshi Biosciences Business Overview Table 73. Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 75. Junshi Biosciences Recent Development Table 76. Pfizer Company Information Table 77. Pfizer Business Overview Table 78. Pfizer PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Pfizer PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 80. Pfizer Recent Development Table 81. Hengrui Pharmaceuticals Company Information Table 82. Hengrui Pharmaceuticals Business Overview Table 83. Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 85. Hengrui Pharmaceuticals Recent Development Table 86. Roche Company Information Table 87. Roche Business Overview Table 88. Roche PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Roche PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 90. Roche Recent Development Table 91. Regeneron Pharmaceuticals Company Information Table 92. Regeneron Pharmaceuticals Business Overview Table 93. Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 95. Regeneron Pharmaceuticals Recent Development Table 96. Bristol Myers Squibb Company Information Table 97. Bristol Myers Squibb Business Overview Table 98. Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 100. Bristol Myers Squibb Recent Development Table 101. AstraZeneca Company Information Table 102. AstraZeneca Business Overview Table 103. AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 105. AstraZeneca Recent Development Table 106. Key Raw Materials Table 107. Raw Materials Key Suppliers Table 108. PD-1/PD-L1 Checkpoint Inhibitors Distributors List Table 109. PD-1/PD-L1 Checkpoint Inhibitors Customers List Table 110. Research Programs/Design for This Report Table 111. Authors List of This Report Table 112. Secondary Sources Table 113. Primary Sources List of Figures Figure 1. PD-1/PD-L1 Checkpoint Inhibitors Product Image Figure 2. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 4. Global PD-1/PD-L1 Checkpoint Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global PD-1/PD-L1 Checkpoint Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. PD-1 Inhibitors Image Figure 10. PD-L1 Inhibitors Image Figure 11. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume Share by Type (2021-2032) Figure 14. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type (2021-2032) Figure 17. Gastric Cancer Image Figure 18. Squamous Cell Skin Cancer Image Figure 19. Melanoma Image Figure 20. Non-small Cell Lung Cancer Image Figure 21. Other Image Figure 22. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume Share by Application (2021-2032) Figure 25. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application (2021-2032) Figure 28. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America PD-1/PD-L1 Checkpoint Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 33. North America PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 35. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America PD-1/PD-L1 Checkpoint Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 39. South America PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. PD-1/PD-L1 Checkpoint Inhibitors Value Chain Figure 127. Manufacturing Cost Structure Figure 128. PD-1/PD-L1 Checkpoint Inhibitors Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • PD-1 Inhibitors
  • PD-L1 Inhibitors
Applications
  • Gastric Cancer
  • Squamous Cell Skin Cancer
  • Melanoma
  • Non-small Cell Lung Cancer
  • Other
Companies covered
  • Merck
  • Junshi Biosciences
  • Pfizer
  • Hengrui Pharmaceuticals
  • Roche
  • Regeneron Pharmaceuticals
  • Bristol Myers Squibb
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value (2021-2032)
  4. 1.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume (2021-2032)
  5. 1.2.3 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 PD-1/PD-L1 Checkpoint Inhibitors Market Dynamics
  1. 2.1 PD-1/PD-L1 Checkpoint Inhibitors Industry Trends
  2. 2.2 PD-1/PD-L1 Checkpoint Inhibitors Industry Drivers
  3. 2.3 PD-1/PD-L1 Checkpoint Inhibitors Industry Opportunities and Challenges
  4. 2.4 PD-1/PD-L1 Checkpoint Inhibitors Industry Restraints
3 PD-1/PD-L1 Checkpoint Inhibitors Market by Company
  1. 3.1 Global PD-1/PD-L1 Checkpoint Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume by Company (2021-2026)
  4. 3.4 Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Company (2021-2026)
  5. 3.5 Global PD-1/PD-L1 Checkpoint Inhibitors Company Ranking (2024-2026)
  6. 3.6 Global PD-1/PD-L1 Checkpoint Inhibitors Company Manufacturing Base and Headquarters
  7. 3.7 Global PD-1/PD-L1 Checkpoint Inhibitors Company Product Type and Application
  8. 3.8 Global PD-1/PD-L1 Checkpoint Inhibitors Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global PD-1/PD-L1 Checkpoint Inhibitors Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 PD-1/PD-L1 Checkpoint Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 PD-1/PD-L1 Checkpoint Inhibitors Market by Type
  1. 4.1 PD-1/PD-L1 Checkpoint Inhibitors Type Introduction
  2. 4.1.1 PD-1 Inhibitors
  3. 4.1.2 PD-L1 Inhibitors
  4. 4.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume by Type
  5. 4.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume by Type (2021-2032)
  7. 4.2.3 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume Share by Type (2021-2032)
  8. 4.3 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Type
  9. 4.3.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Type (2021-2032)
  11. 4.3.3 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type (2021-2032)
5 PD-1/PD-L1 Checkpoint Inhibitors Market by Application
  1. 5.1 PD-1/PD-L1 Checkpoint Inhibitors Application Introduction
  2. 5.1.1 Gastric Cancer
  3. 5.1.2 Squamous Cell Skin Cancer
  4. 5.1.3 Melanoma
  5. 5.1.4 Non-small Cell Lung Cancer
  6. 5.1.5 Other
  7. 5.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume by Application
  8. 5.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume by Application (2021-2032)
  10. 5.2.3 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Volume Share by Application (2021-2032)
  11. 5.3 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Application
  12. 5.3.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Application (2021-2032)
  14. 5.3.3 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application (2021-2032)
6 PD-1/PD-L1 Checkpoint Inhibitors Regional Sales and Value Analysis
  1. 6.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region: 2021-2026
  4. 6.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region (2027-2032)
  5. 6.3 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Region (2021-2032)
  7. 6.4.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Region: 2021-2026
  8. 6.4.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Region (2027-2032)
  9. 6.5 Global PD-1/PD-L1 Checkpoint Inhibitors Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America PD-1/PD-L1 Checkpoint Inhibitors Sales Value (2021-2032)
  12. 6.6.2 North America PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Value (2021-2032)
  15. 6.7.2 Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America PD-1/PD-L1 Checkpoint Inhibitors Sales Value (2021-2032)
  21. 6.9.2 South America PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Country, 2025 VS 2032
7 PD-1/PD-L1 Checkpoint Inhibitors Country-level Sales and Value Analysis
  1. 7.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2032)
  4. 7.3.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2026)
  5. 7.3.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2027-2032)
  6. 7.4 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Country (2021-2032)
  7. 7.4.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Country (2021-2026)
  8. 7.4.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt PD-1/PD-L1 Checkpoint Inhibitors Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt PD-1/PD-L1 Checkpoint Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck PD-1/PD-L1 Checkpoint Inhibitors Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Junshi Biosciences
  8. 8.2.1 Junshi Biosciences Company Information
  9. 8.2.2 Junshi Biosciences Business Overview
  10. 8.2.3 Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  12. 8.2.5 Junshi Biosciences Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer PD-1/PD-L1 Checkpoint Inhibitors Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Hengrui Pharmaceuticals
  20. 8.4.1 Hengrui Pharmaceuticals Company Information
  21. 8.4.2 Hengrui Pharmaceuticals Business Overview
  22. 8.4.3 Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  24. 8.4.5 Hengrui Pharmaceuticals Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche PD-1/PD-L1 Checkpoint Inhibitors Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Roche PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Regeneron Pharmaceuticals
  32. 8.6.1 Regeneron Pharmaceuticals Company Information
  33. 8.6.2 Regeneron Pharmaceuticals Business Overview
  34. 8.6.3 Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  36. 8.6.5 Regeneron Pharmaceuticals Recent Developments
  37. 8.7 Bristol Myers Squibb
  38. 8.7.1 Bristol Myers Squibb Company Information
  39. 8.7.2 Bristol Myers Squibb Business Overview
  40. 8.7.3 Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  42. 8.7.5 Bristol Myers Squibb Recent Developments
  43. 8.8 AstraZeneca
  44. 8.8.1 AstraZeneca Company Information
  45. 8.8.2 AstraZeneca Business Overview
  46. 8.8.3 AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  48. 8.8.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PD-1/PD-L1 Checkpoint Inhibitors Value Chain Analysis
  2. 9.1.1 PD-1/PD-L1 Checkpoint Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PD-1/PD-L1 Checkpoint Inhibitors Sales Mode & Process
  6. 9.2 PD-1/PD-L1 Checkpoint Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PD-1/PD-L1 Checkpoint Inhibitors Distributors
  9. 9.2.3 PD-1/PD-L1 Checkpoint Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst